The granting of Australian Patent No. 2013257212 is for a technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, known as receptacles, can be independent of the dressings that cover infusion sites during IV therapy or integrated within. This Australian grant comes on the heels of the company announcing an Australia and New Zealand distribution agreement with New Medical, a supplier of medical consumables, devices and patient monitoring accessories.
“Our research and development efforts allow us to continually innovate,” said Gary Warren, president and CEO of ivWatch. “Protecting the resulting breakthroughs of those efforts as we expand into new markets ensures patients have highly effective early detection technology no matter where they are receiving medical treatment.”
ivWatch patented technology addresses patient harm caused by peripheral IV infiltration and extravasation events head-on, something many medical device companies and health care systems have attempted over the past 30 years. ivWatch succeeded by solving motion issues related to continuous peripheral IV therapy monitoring.
This core technology is related to ivWatch’s fourth Japanese patent grant, Registration No. 6396904, for mitigating the effects of tissue blood volume changes. This patent describes methods used by ivWatch to extract meaningful signals from biosensors where patient motion produces unwanted noise. By mitigating the effects of changing tissue blood volume, the system minimizes “false” notifications. Reliable early detection of these events paves the way for a new standard of care to minimize injuries associated with the common complication of IV therapy.
ivWatch LLC is a medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. The firm is focused on eliminating patient harm caused by infiltrations and extravasations. Through its monitored IV solutions, ivWatch helps minimize the risks associated with adverse IV events.